Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr2.29
kr0.25(10.92%)
At close: 4:00 PM EDT
kr2.29
kr0.25(10.92%)
Day’s Range― - ―
52-Week Rangekr2.14 - kr4.07
Previous CloseN/A
Volume40.71K
Average Volume (3M)133.41K
Market Cap
kr154.02M
Enterprise Valuekr121.90M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Leverage / Positive EquityLow debt relative to equity gives Initiator Pharma financial flexibility over the medium term, reducing immediate refinancing pressure. Positive equity, despite declines, supports the company’s ability to fund clinical programs and negotiate partnerships without heavy near-term reliance on high-cost debt.
Focused Clinical-stage PipelineA concentrated, proprietary small-molecule pipeline addressing unmet CNS and male sexual health needs provides clear strategic focus. This specialization can enable deeper R&D expertise, targeted regulatory strategy, and attractive partnering/licensing opportunities that persist beyond short-term market cycles.
Improving Free Cash Flow DynamicsAlthough FCF remains negative, a material improvement and FCF that is a lower multiple of net loss indicates better cash conversion. That trend reduces near-term financing urgency and signals management is exercising cost control that can extend runway while clinical milestones are pursued.
Bears Say
No Revenue And Widening LossesSustained pre-revenue status with materially larger losses erodes capitalization and heightens dependency on external financing. Continued negative profitability limits internal reinvestment capacity and increases dilution or restructuring risk if clinical progress or financing windows slip.
Persistent Cash Burn And Funding RiskHigh operating cash outflows with declining equity signal the company will likely need external capital within months. Reliance on financing raises dilution risk and could force unfavorable partnership terms or program prioritization, constraining long-term strategic optionality.
Very Limited Internal ResourcesA one-person reported headcount highlights execution and operational concentration risk: limited internal capability to run multiple trials, scale regulatory operations, or commercialize. This structurally increases dependence on external CROs, partners, and third parties over the medium term.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.14 and its highest was kr4.07 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr154.02M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 21 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.